AstraZeneca-Merck Lynparza gets EMA's positive recommendation
Drugmakers AstraZeneca Plc and Merck& Co Inc said on Monday their blockbluster cancer drug, Lynparza, has received positive recommendation from the European Medicines Agency (EMA) as a maintenance treatment for a form of pancreatic cancer. (Source: Reuters: Health)
Source: Reuters: Health - June 1, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

RefleXion to collaborate with Merck on clinical trial
Radiation therapy equipment developer RefleXion Medical has announced a clinical...Read more on AuntMinnie.comRelated Reading: RefleXion raises $100M in equity round RefleXion sells first X1 rad therapy machine RefleXion gets FDA nod for rad therapy RefleXion files 510(k), opens manufacturing facility RefleXion Medical secures $60M loan (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 29, 2020 Category: Radiology Source Type: news

Merck Leaps Into COVID-19 Development Fray With Vaccine, Drug Deals Merck Leaps Into COVID-19 Development Fray With Vaccine, Drug Deals
Merck, which has largely kept to the sidelines of the race for COVID-19 treatments, said it was buying Austrian vaccine maker Themis Bioscience and would collaborate with research nonprofit IAVI to develop two separate vaccines.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - May 27, 2020 Category: Intensive Care Tags: Infectious Diseases News Source Type: news

Merck adopts ‘error catastrophe’ coronavirus drug
Pill that aims to force virus to mutate to self-destruction set for extensive clinical trials in US and UK (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - May 27, 2020 Category: Pharmaceuticals Source Type: news

Merck to buy Austrian vaccine maker as it jumps into COVID-19 race
Merck& Co Inc , which has largely kept to the sidelines of the race for COVID-19 treatments, said it was buying Austrian vaccine maker Themis Bioscience and would collaborate with research nonprofit IAVI to develop two separate vaccines. (Source: Reuters: Health)
Source: Reuters: Health - May 26, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

Merck makes big push into Covid-19 arena with three new deals, including one with Miami biotech
Merck& Co. expanded its efforts to prevent and treat Covid-19 in a big way Tuesday with three deals aimed at developing both vaccines and therapies for the new strain of the coronavirus. In one deal, Merck (NYSE: MRK) said it has reached an agreement to acquire Themis Bioscience, an Austrian vaccine developer. Merck also announced a Covid-19 vaccine collaboration with IAVI, a nonprofit organization, and a partnership with Miami-based Ridgeback Biotherapeutics to develop Covid-19 therapies. Dr.… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 26, 2020 Category: Biotechnology Authors: John George Source Type: news

Merck chief casts doubt on coronavirus vaccine timeframe
Ken Frazier calls 12 to 18-month targets ‘very aggressive’ as he announces biotech acquisition (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - May 26, 2020 Category: Pharmaceuticals Source Type: news

Merck makes big push into Covid-19 arena with three new deals
Merck& Co. expanded its efforts to prevent and treat Covid-19 in a big way Tuesday with three deals aimed at developing both vaccines and therapies for the new strain of the coronavirus. In one deal, Merck (NYSE: MRK) said it has reached an agreement to acquire Themis Bioscience, an Austrian vaccine developer. Merck also announced a Covid-19 vaccine collaboration with IAVI, a nonprofit organization, and a partnership with Ridgeback Biotherapeutics to develop Covid-19 therapies. Dr. Roger M. Perlmutter,… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 26, 2020 Category: Biotechnology Authors: John George Source Type: news

AstraZeneca-Merck's Lynparza gets U.S. FDA nod for prostate cancer treatment
The U.S. Food and Drug Administration approved AstraZeneca Plc and Merck& Co Inc's Lynparza as a treatment for a form of prostate cancer, the companies said in a joint statement on Wednesday. (Source: Reuters: Health)
Source: Reuters: Health - May 20, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

Lynparza Approved in the US for HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer
20 May 2020 -- AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck& Co., Inc. inside the US and Canada) today announced that Lynparza (olaparib) has been approved in the US for patients with homologous recombination repair (HRR)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 20, 2020 Category: Drugs & Pharmacology Source Type: news

FDA approves Bristol-Myers combo therapy for lung cancer
The U.S. Food and Drug Administration on Friday approved Bristol Myers Squibb Co's combination therapy for previously untreated patients with a form of lung cancer, a much-needed boost as the company battles the dominance of Merck's Keytruda. (Source: Reuters: Health)
Source: Reuters: Health - May 15, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

Lynparza (olaparib) Approved by FDA as First-Line Maintenance Treatment with Bevacizumab for HRD-Positive Advanced Ovarian Cancer
KENILWORTH, N.J.--(BUSINESS WIRE)--May 8, 2020 -- AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Lynparza in combination with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 8, 2020 Category: Drugs & Pharmacology Source Type: news

FDA Approves Merck ’s Keytruda (pembrolizumab) for Use at an Additional Recommended Dose of 400 mg Every Six Weeks for All Approved Adult Indications
KENILWORTH, N.J.--(BUSINESS WIRE) April 28, 2020 --Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an additional recommended dosage of 400 mg every... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 29, 2020 Category: Drugs & Pharmacology Source Type: news

New startup with local ties testing compound with Mayo Clinic to ‘starve’ COVID-19
The startup's CEO is a former Merck executive who previously led two life sciences companies in the Philadelphia suburbs. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 17, 2020 Category: Biotechnology Authors: John George Source Type: news

Lilly, Merck and Pfizer empower team members to volunteer on COVID-19 frontlines
As biopharmaceutical companies continue tofight COVID-19 through research and development, three companies havecreated programs empowering employees with medical or laboratory expertise to completely or partially pause their current roles and volunteer their medical skills to help their local health care organizations. The companies will support their efforts by maintaining the members ’ base pay and providing full benefits. This is just one example of our membership supporting thoseon the frontlines. I was fortunate to connect with four biopharmaceutical company employees who are answering the call to volunteer thei...
Source: The Catalyst - April 15, 2020 Category: Pharmaceuticals Tags: PhRMA Member Company Coronavirus Source Type: news

Up close and personal: The Thomas D ’Hooghe story
While his friends were easing into retirement, Thomas D ’Hooghe MD, 55, was sleepless with excitement at the thought of reinventing himself by jumping from academia to pharma.   It is a move he would recommend to anyone. “It was the best thing I ever did,” says the Vice-President and Head Global Medical Affairs, Fertility at Merck, sitting down with me and sharing his thoughts about passion, purpose, leading people and making a difference.  Origins Working in healthcare was always in his blood. In high school it was never a question; D ’Hooghe would study medicine. It was an id...
Source: EyeForPharma - April 14, 2020 Category: Pharmaceuticals Authors: Jill Donahue Source Type: news

FDA Approves Koselugo (selumetinib) for Pediatric Patients with Neurofibromatosis Type 1 Plexiform Neurofibromas
13 April 2020 -- AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck& Co., Inc. inside the US and Canada) today announced that the US Food and Drug Administration (FDA) has approved the kinase inhibitor Koselugo (selumetinib)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 14, 2020 Category: Drugs & Pharmacology Source Type: news

FDA approves first ever treatment for neurofibromatosis
(Children's Tumor Foundation) The FDA has approved Koselugo (selumetinib) for use in patients with inoperable plexiform neurofibromas, a common manifestation in the disease neurofibromatosis type one (NF1). The FDA's approval of AstraZeneca's and MSD (Merck)'s submission is a major milestone for patients living with neurofibromatosis (NF), a genetic disorder that causes tumors to grow on nerves throughout the body. Affecting 1 in 3,000 people of all populations equally, this announcement is the first ever approved treatment for NF. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 13, 2020 Category: Cancer & Oncology Source Type: news

EMD Serono and Pfizer Receive US FDA Breakthrough Therapy Designation and Submit Application for BAVENCIO(R) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Not intended for UK-based media - Breakthrough Therapy Designation and Submission based on positive Phase III JAVELIN Bladder 100 study results - Supplemental Biologics License Application being reviewed under FDA Real-Time Oncology Review (RTOR) pil... Biopharmaceuticals, Oncology, FDA EMD Serono, Merck KGaA, Pfizer, avelumab, BAVENCIO, urothelial carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 9, 2020 Category: Pharmaceuticals Source Type: news

Merck ’s Dr. Julie Gerberding on the threat of antimicrobial resistance and COVID-19
As America ’s biopharmaceutical companies workaround the clock to combat COVID-19, a disease caused by a novel strain of coronavirus, now is an important time to consider how we can prepare for the next public health emergency: Antimicrobial resistance (AMR). AMR occurs when microorganisms such as bacteria, viruses, fungi and parasites change in ways that make the medications used to cure the infections they cause ineffective. According to the Centers for Disease Control and Prevention (CDC), more than 2.8 million antibiotic-resistant infections occur in the U.S. each year, and more than 35,000 people die as a r...
Source: The Catalyst - April 6, 2020 Category: Pharmaceuticals Tags: Research and Development PhRMA Member Company Infectious Diseases Coronavirus Source Type: news

Merck, Pfizer, Eli Lilly launch worker volunteer programs to aid in coronavirus fight
Major drugmakers Merck& Co. Inc.,, Pfizer Inc. and Eli Lilly and Co. are joining together to establish volunteer programs to enable employees who are licensed medical professionals to aid in the fight against COVID-19 while maintaining their base pay. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 1, 2020 Category: Pharmaceuticals Authors: I-Chun Chen Source Type: news

How should pharma approach patient collaboration in the 2020s?
From the growing range of patient entities through to new possibilities stemming from technology and patient-generated data, pharma has more and more ways to innovate when it comes to collaborating with patients. 
  Now pharma needs to identify the ones that will move the dial commercially. “Clearly there is a shift from patient engagement as a nice-to-have, feel-good activity, to something which is more strategic,” says Vanessa Pott, Director, Patient Advocacy& Strategic Partnerships at Merck. “It’s really important for us to stay abreast of all the external trends.”  To...
Source: EyeForPharma - April 1, 2020 Category: Pharmaceuticals Authors: Lucy Fulford Source Type: news

Colorado nurse who contracted coronavirus describes how symptoms progressed from sniffles to aches
Lisa Merck, 50, from Crested Butte, Colorado, felt sniffles after returning from a two-week trip to Hawaii. Within days, she began feeling body aches, shortness of breath and a fever. (Source: the Mail online | Health)
Source: the Mail online | Health - March 16, 2020 Category: Consumer Health News Source Type: news

Advancing through partnerships
  If any reminder were needed of the power of collaboration in healthcare, it is the global efforts underway to stem the current coronavirus outbreak and to develop treatments for it.  Chris Round, Merck ’s Head of International Operations& Global Core Franchises, speaking to eyeforpharma ahead of his eyeforpharma Barcelona Conference 2020 keynote, mentions that Merck is lending its heft to industry efforts to help tackle the emergency. “The industry has shown what it is capable of with HIV and Ebola in the past, so I am hopeful that the industry can pull together very fast.”  Partne...
Source: EyeForPharma - March 14, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news

Online hospitals – the journey from East to West
Imagine a world where you are sitting at your desk in the offices of a large company and you start to feel unwell. You take the lift to the ground floor to a vending machine in the lobby. You login and explain your symptoms to the machine. It gives you a diagnosis, prescribes your medication, you pay for it and it dispenses it on the spot. Far-fetched? No. This is the Ping An Good Doctor ‘One Minute Clinic’ launched by Chinese health-tech company Ping An Healthcare and Technology in April last year. Powered by Artificial Intelligence (AI), when a patient makes an inquiry, an algorithm identifies and s...
Source: EyeForPharma - March 13, 2020 Category: Pharmaceuticals Authors: Katie Osborne Source Type: news

EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
Not intended for UK-based media ROCKLAND, Mass. and NEW YORK, March 13, 2020 -- (Healthcare Sales & Marketing Network) -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) tod... Biopharmaceuticals, Oncology EMD Serono, Merck KGaA, Pfizer, avelumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 13, 2020 Category: Pharmaceuticals Source Type: news

ICYMI: Continued biopharmaceutical action on COVID-19
This week, PhRMA and senior executives and researchers from four member companies met with key policy makers on Capitol Hill to discuss the industry ’s response to COVID-19, caused by a novel strain of coronavirus. Daniel O’Day of Gilead Sciences, Julie Louise Gerberding, M.D., M.P.H. of Merck& Co., Inc, Paul Stoffels, M.D. of Johnson& Johnson, John Shiver, Ph.D. of Sanofi Pasteur and Steve Ubl of PhRMA were crucial contributors to the dialogue and offered updates and insights on their companies ’ and the industry's progress in the fight against the coronavirus. (Source: The Catalyst)
Source: The Catalyst - March 6, 2020 Category: Pharmaceuticals Tags: PhRMA Member Company Vaccines Infectious Diseases Source Type: news

What Causes Neutropenia?
Discussion Neuropenia is defined as a neutrophil count
Source: PediatricEducation.org - March 2, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Drug May Help Tough-to-Treat Chronic Cough
The trial was funded by the drug's maker, Merck, and involved 253 American and British participants. All had suffered from an unexplained or untreatable cough that had lasted for an average of almost 15 years. (Source: WebMD Health)
Source: WebMD Health - February 26, 2020 Category: Consumer Health News Source Type: news

Scientists develop non-invasive method to predict onset of dementia
(Regenstrief Institute) Information gathered from routine visits to the doctor is enough to accurately predict a person's risk of developing Alzheimer's disease and related dementias, according to new research led by scientists from Regenstrief Institute, Indiana University and Merck. The researchers developed and tested machine learning algorithms using data from electronic medical records to identify patients who may be at risk for developing the dementia. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 11, 2020 Category: International Medicine & Public Health Source Type: news

Merck: spin doctor 
On paper, the spin-off looks promising, but there is some pause for thought (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - February 5, 2020 Category: Pharmaceuticals Source Type: news

Merck to streamline business, separate into two companies
Merck& Co. Inc. unveiled plans Wednesday to spin off products from its women ’s health and biosimilars businesses, along with certain legacy brands, into a new independent and publicly traded company. Going forward, Merck (NYSE: MRK) will focus on its oncology, vaccines, hospital medicine and animal health segments. Merck expects the spinoff to be completed by the first half of 2021. The pharmaceutical giant anticipates cost savings of more than $1.5 billion — primarily in areas such as manufacturing… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 5, 2020 Category: Biotechnology Authors: John George Source Type: news

Merck to spin off assets in effort to streamline its business
New company with $6.5bn in revenue will include women’s health unit and legacy brands (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - February 5, 2020 Category: Pharmaceuticals Source Type: news

Merck to streamline business, separate into two companies
Merck& Co. Inc. unveiled plans Wednesday to spin off products from its women ’s health and biosimilars businesses, along with certain legacy brands, into a new independent and publicly traded company. Going forward, Merck (NYSE: MRK) will focus on its oncology, vaccines, hospital medicine and animal health segments. "Over the past several years, we have purposefully shi fted the focus of our efforts and resources to our best opportunities for growth," said Merck Chairman and CEO Kenneth C. Frazier,… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 5, 2020 Category: Pharmaceuticals Authors: John George Source Type: news

Merck to spin off women's health and biosimilar drugs, focus on Keytruda
Merck& Co Inc said on Wednesday it intends to spin off its women's health, biosimilar drugs and older products into a new publicly traded company, a move that will allow the company to focus on growth drivers like cancer drug Keytruda and vaccines. (Source: Reuters: Health)
Source: Reuters: Health - February 5, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

Merck to spin off assets in bid to streamline its business
New company with $6.5bn in revenue will include women’s health unit and legacy brands (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - February 5, 2020 Category: Pharmaceuticals Source Type: news

Merck Has A Great Future, Because It Has A Soul: Ken Frazier
In this uplifting and fascinating conversation, Ken Frazier, the highly successful CEO of pharmaceutical giant Merck, talks about a company having a soul and other interesting topics, including how he rose up from a very humble background. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - February 4, 2020 Category: Pharmaceuticals Authors: Steve Forbes, Forbes Staff Source Type: news

Merck donates one billionth praziquantel tablet
Merck, a leading science and technology company, today announced that it has already donated 1 billion tablets of praziquantel, the standard medication for the treatment of schistosomiasis, to the World Health Organization (WHO). This marks a crucial milestone on the journey to the elimination of this neglected tropical disease (NTD) which mostly affects children in poor and rural communities. (Source: World Pharma News)
Source: World Pharma News - January 30, 2020 Category: Pharmaceuticals Tags: Featured Merck Group Business and Industry Source Type: news

FDA Approves Merck ’s Dificid (fidaxomicin) to Treat Clostridioides difficile in Children Aged Six Months and Older
KENILWORTH, N.J.--(BUSINESS WIRE)-- Monday, January 27, 2020 -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for Dificid... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 27, 2020 Category: Drugs & Pharmacology Source Type: news

Providence St. Joseph Health acquires Health Management Resource from Merck, CVS publishes 2020 health predictions and other digital health news briefs
Also: Hims and Hers expands to all 50 states; VC firm Freestyle Capital offers Meru to portfolio companies.   (Source: mobihealthnews)
Source: mobihealthnews - January 22, 2020 Category: Information Technology Source Type: news

Lynparza regulatory submission granted Priority Review in the US for 1st-line maintenance treatment with bevacizumab in advanced ovarian cancer
AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced that a supplemental New Drug Application for Lynparza (olaparib) in combination with bevacizumab has been accepted and granted Priority Review in the US for the maintenance treatment of patients with advanced ovarian cancer who are in complete or partial response to 1st-line platinum-based chemotherapy with bevacizumab. (Source: World Pharma News)
Source: World Pharma News - January 15, 2020 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Into pharma's roaring twenties
“I drained the last of my cocktail, gazing up at the ceiling. It was one of those moments that curls the hairs on your neck. At once, the grand scale of this labyrinth of cathedrals became clear, the desert wind blowing through the clever hieroglyphics carved into every available surface. I turned my head back down to ground level just in time to see the man draw back his fist in anger, and then.And then.With a piercing shriek, he lunged straight at my jaw –”Do you ever wake from a dream, marvelling at the inventiveness and detail of your subconscious mind? That disorienting moment where you lie blinking ...
Source: EyeForPharma - January 14, 2020 Category: Pharmaceuticals Authors: Paul Simms Source Type: news

Pharma ’s new ally: the caregiver
While pharma and the wider healthcare sector are making patients more central to their innovation efforts these days, little consideration is given to caregivers. The role of the unpaid caregiver is one they would do well to consider more. Caregivers comprise an enormous, and largely untapped, reservoir of information and wisdom about the individuals they provide care for, says Schiffon Wong, Executive Director, Global Evidence& Value Development at EMD Serono.   “There is a significant opportunity when it comes to caregiver input into medical product evaluation. Understanding this can further our ...
Source: EyeForPharma - January 12, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news

Merck's Keytruda wins U.S. FDA approval for bladder cancer
The U.S. Food and Drug Administration said on Wednesday it approved Merck& Co Inc's Keytruda for a hard-to-treat form of bladder cancer, making it the first new treatment for the cancer in more than two decades. (Source: Reuters: Health)
Source: Reuters: Health - January 8, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Approves Keytruda (pembrolizumab) for Patients With BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer
KENILWORTH, N.J.--(BUSINESS WIRE) January 8, 2020 --Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, as... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 8, 2020 Category: Drugs & Pharmacology Source Type: news

Merck's Keytruda shows mixed results in phase 3 trial for small cell lung cancer
Merck& Co said a phase 3 trial of cancer drug Keytruda in combination with chemotherapy showed an increase in  the amount of time patients lived with small cell lung cancer without it getting worse, but did not extend overall survival. (Source: Reuters: Health)
Source: Reuters: Health - January 6, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

Novartis, Merck and Allergan Join Those Raising U.S. Drug Prices for 2020 Novartis, Merck and Allergan Join Those Raising U.S. Drug Prices for 2020
Novartis AG, Merck& Co Inc and Allergan Plc were among companies that raised U.S. prices on more than 100 prescription medicines on Friday, bringing the tally to 445 drugs that will cost more in 2020, according to data analyzed by healthcare research firm 3 Axis Advisors.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 6, 2020 Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news

Merck signs cancer collaboration deal valued at up to $2.55B
Merck entered into an exclusive worldwide research collaboration and license agreement Monday with Taiho Pharmaceutical Co. Ltd. and Astex Pharmaceuticals, in a backloaded deal valued at up to $2.55 billion. The partnership is part of Merck's ongoing efforts to broaden its pipeline of drug candidates targeting cancer, the company's most important therapeutic category. Both Taiho of Tokyo and Astex in Pleasanton, California, are developing small molecule inhibitors for treating cancer patients.… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 6, 2020 Category: Pharmaceuticals Authors: John George Source Type: news

Novartis, Merck and Allergan join those raising U.S. drug prices for 2020
Novartis AG, Merck& Co Inc and Allergan Plc were among companies that raised U.S. prices on more than 100 prescription medicines on Friday, bringing the tally to 445 drugs that will cost more in 2020, according to data analyzed by healthcare research firm 3 Axis Advisors. (Source: Reuters: Health)
Source: Reuters: Health - January 3, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

Wisconsin's Promega accesses CRISPR technology through licensing deal with Merck unit
Promega Corp., the Fitchburg-based biotechnology company, has signed a licensing agreement with MilliporeSigma, the U.S. life sciences business of German pharmaceutical and chemical company Merck KGaA, to use its genome-editing technology to create research products and services, including those for drug development. The agreement will give Promega access to MilliporeSigma's CRISPR platform to create new research products for investigating endogenous biology, which can help in "determining drug… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 2, 2020 Category: Biotechnology Authors: Nick Williams Source Type: news